Transposition-based therapies
Gene therapy compositions and methods are provided that make use of transposases and/or chimeric transposases for targeted transposition, including engineered enzymes and nucleic acids encoding the same. The provided compositions and methods are suitable of treating, for example, an inherited or acquired disease in a patient, as well as treating and/or mitigating a variety of diseases.
1. A composition comprising a nucleic acid encoding a transposase enzyme, wherein the transposase enzyme comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2 and has a non-polar aliphatic amino acid at position 2 of SEQ ID NO: 2, wherein the transposase enzyme further comprises a substitution C13X 2 , wherein X 2 is selected from lysine (K), arginine (R), and histidine (H).
2. The composition of claim 1 , wherein the non-polar aliphatic amino acid is selected from alanine (A), glycine (G), valine (V), leucine (L), isoleucine (I), and proline (P).
3. The composition of claim 2 , wherein the non-polar aliphatic amino acid is alanine (A).
4. The composition of claim 1 , wherein the transposase enzyme further comprises a substitution S8X 1 , wherein X 1 is selected from alanine (A), glycine (G), valine (V), leucine (L), isoleucine (I), and proline (P).
5. The composition of claim 4 , wherein X 1 is proline (P).
6. The composition of claim 1 , wherein X 2 is arginine (R).
7. The composition of claim 1 , wherein the transposase enzyme does not have additional amino acid residues at the C terminus relative to SEQ ID NO: 2.
8. The composition of claim 1 , wherein the transposase enzyme comprises an amino acid sequence having at least 98% identity to SEQ ID NO: 2.
9. The composition of claim 1 , wherein the nucleic acid further encodes a transcription activator-like effector (TALE) DNA binding domain (DBD), or a nuclease-deficient Cas9 (dCas9) connected to the transposase enzyme.
10. The composition of claim 9 , wherein the transposase enzyme is capable of inserting a transposon at a TA dinucleotide site or a TTAA (SEQ ID NO: 1) tetranucleotide site in a genomic safe harbor site (GSHS) of a nucleic acid molecule.
11. The composition of claim 10 , wherein the TALE DBD or dCas9 is suitable for directing the transposase enzyme to the GSHS sequence.
12. The composition of claim 10 , wherein the GSHS is selected from adeno-associated virus site 1 (AAVS1), chemokine (C-C motif) receptor 5 (CCR5) gene, HIV-1 coreceptor, and human Rosa26 locus.
13. The composition of claim 1 , wherein the nucleic acid is co-formulated with a nucleic acid encoding a transposon.
14. The composition of claim 13 , wherein the composition is in the form of a lipid nanoparticle (LNP).
15. A composition comprising a nucleic acid encoding a transposase enzyme, wherein the transposase enzyme comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2 and has a non-polar aliphatic amino acid at position 2 of SEQ ID NO: 2, wherein the transposase enzyme further comprises a substitution N125X 3 , wherein X 3 is selected from is selected from lysine (K), arginine (R), and histidine (H).
16. The composition of claim 15 , wherein X 3 is lysine (K).
17. The composition of claim 15 , wherein the non-polar aliphatic amino acid is selected from alanine (A), glycine (G), valine (V), leucine (L), isoleucine (I), and proline (P).
18. The composition of claim 15 , wherein the nucleic acid further encodes a transcription activator-like effector (TALE) DNA binding domain (DBD), or a nuclease-deficient Cas9 (dCas9) connected to the transposase enzyme.
19. A composition comprising a nucleic acid encoding a transposase enzyme, wherein the transposase enzyme comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2 and has a non-polar aliphatic amino acid at position 2 of SEQ ID NO: 2, wherein the transposase enzyme further comprises two or more of substitutions S8P, C13R, and N125K.
20. The composition of claim 19 , wherein the non-polar aliphatic amino acid is selected from alanine (A), glycine (G), valine (V), leucine (L), isoleucine (I), and proline (P).
21. The composition of claim 19 , wherein the nucleic acid further encodes a transcription activator-like effector (TALE) DNA binding domain (DBD), or a nuclease-deficient Cas9 (dCas9) connected to the transposase enzyme.
22. A composition comprising a first nucleic acid encoding a transposase enzyme and a DNA binding domain and a second nucleic acid encoding a transposon,
wherein the transposase enzyme comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO: 2 and comprises two or more of substitutions of S8P, C13R, and N125K,
wherein the transposase enzyme is operatively linked to the DNA binding domain, and
wherein the first nucleic acid and second nucleic acid are contained in a LNP.
23. The composition of claim 22 , wherein the DNA binding domain is a TALE DBD.
24. The composition of claim 22 , wherein the DNA binding domain is a dCas9.
25. The composition of claim 22 , wherein the transposase enzyme does not have additional amino acid residues at the C terminus relative to SEQ ID NO: 2.
26. The composition of claim 25 , wherein the substitutions are S8P and C13R.
27. The composition of claim 23 , wherein the transposase enzyme does not have additional amino acid residues at the C terminus relative to SEQ ID NO: 2.
28. The composition of claim 27 , wherein the substitutions are S8P and C13R.